Ultragenyx Pharmaceutical Inc. (RARE) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Market Cap | 2.27B |
| Enterprise Value | 3.11B |
| P/E Ratio | -4.75 |
| PEG Ratio | 0.98 |
| Price/Sales Ratio | 4.27 |
| Price/Book Ratio | -12.37 |
| Enterprise/Revenue | 5.8 |
| Enterprise/EBITDA | -7.72 |
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | March 31, 2026 |
| Profit Margin | -0.91 |
| Operating Margin | -0.84 |
| Return On Assets | -0.47 |
| Return On Equity | 15.67 |
| Revenue | 673M |
| Revenue/Share | 6.65 |
| Gross Profit | 564M |
| EBITDA | -474M |
| Net Income | -575M |
| Diluted EPS | -5.83 |
| Total Cash | 413M |
| Total Cash/Share | 4.11 |
| Total Debt | 1.2B |
| Total Debt/Equity | -5.08 |
| Current Ratio | 2.02 |
| Book Value Per Share | -2.28 |
| 52-Week Change | -21.18 |
| 52-Week High | 42.37 |
| 52-Week Low | 18.29 |
| Moving Average 50 Days | 24.42 |
| Moving Average 200 Days | 27.02 |
| Average Volume | 1.83M |
| Shares Outstanding | 98.49M |
| % Held by Institutions | 99.5 |
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |